Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) - Pipeline Review, H1 2016

  • ID: 3802809
  • Report
  • 58 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • CanBas Co., Ltd.
  • Eli Lilly and Company
  • Genentech, Inc.
  • Sareum Holdings Plc
  • Vernalis Plc
  • MORE
Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) - Pipeline Review, H1 2016

Summary

‘Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) - Pipeline Review, H1 2016’, provides in depth analysis on Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1)
- The report reviews Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • CanBas Co., Ltd.
  • Eli Lilly and Company
  • Genentech, Inc.
  • Sareum Holdings Plc
  • Vernalis Plc
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) Overview

Therapeutics Development

Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) - Products under Development by Stage of Development

Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) - Products under Development by Therapy Area

Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) - Products under Development by Indication

Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) - Products under Development by Companies

Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) - Products under Development by Universities/Institutes

Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) - Companies Involved in Therapeutics Development

CanBas Co., Ltd.

Cascadian Therapeutics Inc

Eli Lilly and Company

Genentech, Inc.

Sareum Holdings Plc

Vernalis Plc

Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) - Drug Profiles

CBP-501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCT-244747 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCT-245737 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FS-105 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONT-2409 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

prexasertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RG-7741 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-020106 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Chk1 for Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Chk1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

V-158411 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) - Dormant Projects

Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) - Discontinued Products

Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) - Featured News & Press Releases

May 23, 2016: Clinical Trials of CHK1 Inhibitor CCT245737 to Open at the Royal Marsden Hospital

Apr 19, 2016: Oncothyreon Highlights Novel Checkpoint Kinase 1 Inhibitors at American Association for Cancer Research (AACR) Annual Meeting 2016

Apr 05, 2016: CHK1 inhibitor CCT245737 Approved for Clinical Trials in Cancer Patients

Feb 01, 2016: CHK1 Clinical Trial Application Submissions

Dec 15, 2015: CHK1 Clinical Trial Applications

May 12, 2015: Sareum to Present at BioTrinity 2015

Apr 20, 2015: Lilly Releases Early-Stage Pipeline Data On LY2606368 at AACR Annual Meeting 2015

Apr 17, 2013: CanBas Announces Topline Results From Phase II Trial Of CBP501 In Patients With Non-Small Cell Lung Cancer

Jun 04, 2012: CanBas's CBP501 Meets Primary Endpoint In Phase II Study Of Malignant Pleural Mesothelioma

Jan 05, 2012: CanBas's CBP501 Receives Orphan Drug Designation From FDA For Malignant Mesothelioma

Nov 01, 2011: Canbas Enrolls Last Patient In Phase II Trial Of CBP501 As First-Line Treatment Of Malignant Pleural Mesothelioma

Oct 27, 2011: Canbas Announces Last Patient Enrolled In Phase II Trial Of CBP501 As First-Line Treatment Of Non-Small Cell Lung Cancer

Jan 20, 2010: New Molecules SAR-020106 Increase The Effectiveness Of Certain Cancer Therapies

Oct 06, 2009: Sareum And CRT Announce Results Of SAR-020106 At National Cancer Research Institute Cancer Conference

Jul 21, 2009: Vernalis Plc Announces New Oncology Development Candidate V158411

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 58List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by CanBas Co., Ltd., H1 2016

Pipeline by Cascadian Therapeutics Inc, H1 2016

Pipeline by Eli Lilly and Company, H1 2016

Pipeline by Genentech, Inc., H1 2016

Pipeline by Sareum Holdings Plc, H1 2016

Pipeline by Vernalis Plc, H1 2016

Dormant Projects, H1 2016

Discontinued Products, H1 2016 48List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • CanBas Co., Ltd.
  • Eli Lilly and Company
  • Genentech, Inc.
  • Sareum Holdings Plc
  • Vernalis Plc
  • MORE
Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by Companies and remaining by the Universities/Institutes. The author's latest report SerineThreonine-Protein Kinase Chk1 - Pipeline Review, H1 2016, outlays comprehensive information on the Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) Checkpoint kinase 1 or Chk1 is a Serine/threonine-specific protein kinase encoded by the CHEK1 gene. It is required for checkpoint-mediated cell cycle arrest and activation of DNA repair in response to the presence of DNA damage or unreplicated DNA. It binds to and phosphorylates CDC25A, CDC25B and CDC25C. Inhibition of CDC25 leads to increased inhibitory tyrosine phosphorylation of CDK-cyclin complexes and blocks cell cycle progression. It also phosphorylates NEK6. It plays a role in replication fork maintenance through regulation of PCNA. It regulates the transcription of genes that regulate cell-cycle progression through the phosphorylation of histones. The molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 5 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Furthermore, this report also reviews key players involved in Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 5
CanBas Co., Ltd.
Cascadian Therapeutics Inc
Eli Lilly and Company
Genentech, Inc.
Sareum Holdings Plc
Vernalis Plc
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll